Characterization of the molecular signaling pathways underlying protein synthesis-dependent forms of synaptic plasticity, such as late long-term potentiation (L-LTP), can provide insights not only into memory expression/maintenance under physiological conditions but also potential mechanisms associated with the pathogenesis of memory disorders. Here, we report in mice that L-LTP failure induced by the mammalian (mechanistic) target of rapamycin complex 1 (mTORC1) inhibitor rapamycin is reversed by brain-specific genetic deletion of PKR-like ER kinase, PERK (PERK KO), a kinase for eukaryotic initiation factor 2a (eIF2a). In contrast, genetic removal of general control non-derepressible-2, GCN2 (GCN2 KO), another eIF2a kinase, or treatment of hippocampal slices with the PERK inhibitor GSK2606414, does not rescue rapamycin-induced L-LTP failure, suggesting mechanisms independent of eIF2a phosphorylation. Moreover, we demonstrate that phosphorylation of eukaryotic elongation factor 2 (eEF2) is significantly decreased in PERK KO mice but unaltered in GCN2 KO mice or slices treated with the PERK inhibitor. Reduction in eEF2 phosphorylation results in increased general protein synthesis, and thus could contribute to the mTORC1-independent L-LTP in PERK KO mice. We further performed experiments on mutant mice with genetic removal of eEF2K (eEF2K KO), the only known kinase for eEF2, and found that L-LTP in eEF2K KO mice is insensitive to rapamycin. These data, for the first time, connect reduction in PERK activity with the regulation of translation elongation in enabling L-LTP independent of mTORC1. Thus, our findings indicate previously unrecognized levels of complexity in the regulation of protein synthesis-dependent synaptic plasticity.
De novo protein synthesis (mRNA translation) is indispensable for the maintenance of long-term synaptic plasticity, such as long-term potentiation (LTP) and long-term depression Costa-Mattioli et al. 2009; Richter and Klann 2009) . Understanding the molecular signaling pathways associated with protein synthesis-dependent forms of synaptic plasticity can provide insights into memory expression/maintenance under physiological conditions, as well as potential molecular mechanisms associated with the pathogenesis of memory disorders, such as Alzheimer's disease (AD) Ma and Klann 2012) . Protein synthesis takes place in three phases (initiation, elongation, and termination) with multiple translational protein factors required in each phase to facilitate the process. The signaling cascades associated with mammalian (mechanistic) target of rapamycin complex 1 (mTORC1) and eukaryotic initiation factor 2 (eIF2) are among the most intensively studied molecular mechanisms in protein synthesis-dependent forms of synaptic plasticity, learning, and memory (Graber et al. 2013; Trinh and Klann 2013) . Both mTORC1 and eIF2 play critical roles in the highly regulated initiation phase of protein synthesis. Briefly, mTORC1 controls cap-dependent mRNA translation initiation through its downstream target eukaryotic initiation 4E-binding protein 1 (4E-BP1) and synthesis of translational machinery (e.g. ribosomal proteins) encoded by terminal oligopyrimidine mRNAs via its downstream effector p70S6 kinase (p70S6K, or S6K1) (Yang and Guan 2007; Meyuhas and Kahan 2015) . Translational control via eIF2 is mainly achieved by its four kinases (PERK, GCN2, PKR, and HRI), which share a conserved kinase domain but are activated under various circumstances. Nevertheless, activation of all four kinases leads to phosphorylation of eIF2 at its a subunit (eIF2a) on the Ser51 site and subsequent repression of general protein synthesis (Wek et al. 2006 (Wek et al. , 2007 Wek and Cavener 2007; Trinh et al. 2014) . Recent studies reveal a crucial role of PERK in normal cognitive function and link overactive PERK/eIF2a hyperphosphorylation to neurodegenerative diseases, including AD, prion disease, and frontotemporal dementia (Moreno et al. 2012; Trinh et al. 2012; Ma et al. 2013; Radford et al. 2015; Yang et al. 2016) . The mTORC1 and eIF2a pathways are both critical in long-term synaptic plasticity and memory; however, it is unclear whether there is an interaction between the two pathways.
Although much attention has been devoted to the regulation of translation initiation via mTORC1 and eIF2, accumulating evidence suggests that translational control at the elongation phase also plays an important role in the expression of synaptic plasticity and certain forms of memory (Tsokas et al. 2005; Park et al. 2008; Im et al. 2009; Gildish et al. 2012; Taha et al. 2013; Heise et al. 2014 Heise et al. , 2017 . One established mechanism for elongation control is through regulation of eukaryotic elongation factor 2 (eEF2). eEF2 activity is regulated through its only known kinase, eEF2 kinase (eEF2K). Phosphorylation of eEF2 on Thr56 by eEF2K disrupts peptide growth and general protein synthesis (Ryazanov and Davydova 1989; Kenney et al. 2014) . Previous studies, mostly from non-neuronal systems, have identified several signaling molecules functioning as upstream regulators of eEF2K/eEF2, including mTORC1 and AMP-activated protein kinase (AMPK), a central molecular sensor for cellular energy homeostasis (Horman et al. 2002; Taha et al. 2013; Hardie 2014) . It is unknown whether eEF2K/eEF2 signaling is connected to eIF2a and its kinases during neural plasticity and memory.
Here, using both pharmacological and genetic approaches, we investigated potential interactions between the aforementioned signaling pathways controlling mRNA translation in the context of hippocampal late-LTP (L-LTP) in mice. Our findings indicate previously unrecognized levels of complexity in the regulation of protein synthesis-dependent synaptic plasticity.
Materials and methods

Mice
All mice were housed in a barrier facility dedicated to transgenic mice at Wake Forest University School of Medicine. The facility operates in accordance with standards and policies of the US Department of Agriculture's Animal Welfare Information Center (AWIC) and the NIH Guide for Care and Use of Laboratory Animals. Animals were kept on a 12 h light/dark cycle with a regular feeding and cage-cleaning schedule. Three-to six-month-old mice of either sex were used for experimentation. PERK forebrain conditional knockout mice (PERK KO) were generated as described previously (Trinh et al. 2012) . Wild-type (WT) (RRID: IMSR_JAX:000664) control mice were purchased from Jackson Labs. Breeders of GCN2 knockout mice (GCN2 KO) were generously provided by Dr Douglas Cavener of Pennsylvania State University and Dr Eric Klann of New York University. There were no significant alterations in life span, general health, or development of the knockout mouse lines used in our study, based on previous publications and our own observations (Costa-Mattioli et al. 2005; Trinh et al. 2012; Ma et al. 2013) . All genotypes were verified using polymerase chain reaction (PCR). Animals were sorted into groups based on genotype, and thus not randomized and researchers were not blinded to genotype. All experimental protocols were checked and approved by the Institutional Animal Care and Use Committee (IACUC) of Wake Forest University School of Medicine (A14-514). The study was not pre-registered. Animals were monitored for health and killed according to IACUC guidelines prior to experimentation, and a minimum number of animals were used in order to meet statistical significance.
Hippocampal slice preparation and electrophysiology Acute 400 lm transverse hippocampal slices were prepared using a Leica (Wetzlar, Germany) VT1200S vibratome as described previously (Yang et al. 2016) . Slices were maintained before experimentation at room temperature for at least 2 h in artificial cerebrospinal fluid containing (in mM) 118 NaCl, 3.5 KCl, 2.5 CaCl 2 , 1.3 MgSO 4 , 1.25 NaH 2 PO 4 , and 15 glucose, bubbled with 95% O 2 /5% CO 2 . For electrophysiology, monophasic, constantcurrent stimuli (100 ls) were delivered with a bipolar silver electrode placed in the stratum radiatum of area CA3. Field excitatory postsynaptic potentials (fEPSPs) were recorded using a glass microelectrode from the stratum radiatum of area CA1. Late-LTP (L-LTP) was induced using high-frequency stimulation (HFS) consisting of two 1-s 100 Hz trains separated by 60 sec, each delivered at 70-80% of the intensity that evoked spiked fEPSPs.
Drug treatment
All drugs were prepared as stock solutions in dimethylsulfoxide and diluted to final concentrations in artificial cerebrospinal fluid before use. Final drug concentrations were as follows: rapamycin (1 lM, Calbiochem, San Diego, CA, USA/Millipore Corporation, Bedford, MA, USA), PERK inhibitor GSK2606414 (1 lM, Calbiochem/ Millipore), and anisomycin (40 lM, Tocris Cookson, Ballwin, MO, USA). Incubation of hippocampal slices was performed in either recording chambers or maintenance chambers as needed.
Western blotting
Hippocampal slices were flash-frozen on dry ice and sonicated as previously described (Beckelman et al. 2016) . Samples containing equal amounts of protein lysate were loaded on 4-12% Tris-glycine sodium dodecyl sulfate-polyacrylamide gel electrophoresis gels for standard gel electrophoresis. Following transfer, nitrocellulose membranes were probed overnight at 4°C using the following primary antibodies Protein bands were visualized using chemiluminescence (ClarityTM ECL; Biorad, Hercules, CA, USA) and the Biorad ChemiDocTM MP imaging system. Densitometric analysis was performed using ImageJ. Data were normalized to glyceraldehyde-3-phosphate dehydrogenase (for total protein analysis) or relevant total proteins (for phosphoprotein analysis) unless otherwise specified. All antibody validation data are available from their source company.
SUnSET protein synthesis assay As described , hippocampal slices were incubated with puromycin (1 lg/mL) for 60 min. At the end of the experiment, slices were harvested and flash-frozen on dry ice. Area CA1 was micro-dissected and protein lysates were prepared for western blotting. Puromycin-labeled proteins were identified using antipuromycin antibody (1 : 5000; Millipore Cat# AB3258, RRID: AB_91423). Protein synthesis levels were assessed by taking total lane density in the molecular weight of 10-250 kDa.
Immunofluorescence and confocal microscopy Hippocampal slices were fixed overnight in ice-cold 4% paraformaldehyde in phosphate-buffered saline. Free-floating sections were sub-sectioned to 40 lm using a Leica VT1200S vibratome and permeabilized with 0.3% TritonX-100. Sections were incubated with signal enhancer for 30 m, blocked with 10% normal goat serum, 0.1% sodium azide, and 1% bovine serum albumin in phosphate-buffered saline for 5 h, and incubated overnight with primary antibody for phospho-eEF2 (Thr56) (1 : 200). Alexa Fluor 488 secondary antibody (Thermo Fisher, Waltham, MA, USA Catalog #:R37120, RRID:AB_2556548) was used. The sections were imaged using an Olympus FV1200 Confocal microscope at 63X. All parameters (pinhole, contrast, gain, and offset) were held constant for all sections across the same experiment.
Statistical analysis
Data are presented as mean + SEM. For comparisons between two groups, a two-tailed independent Student's t-test was used. Error probabilities of p < 0.05 were considered statistically significant. Data were analyzed using GraphPad Prism software. Outliers were determined via Grubbs test with a criterion of p < 0.05 for removal. Sample size calculation was not used to predetermine the sample size.
Results
L-LTP failure induced by the mTORC1 inhibitor rapamycin is reversed by genetic removal of eIF2a kinase PERK Research of over more than a decade has established the critical role of mTORC1 in long-term synaptic plasticity and memory Graber et al. 2013 ). In accordance with previous studies, we found that late-LTP (L-LTP) induced by strong HFS was blocked when hippocampal slices were treated with the mTORC1 inhibitor rapamycin (1 lM) (Fig. 1a-c) . Next, we performed L-LTP experiments on slices derived from a line of transgenic mice in which the eIF2a kinase PERK was genetically removed in the brain, resulting in decreased eIF2a phosphorylation and increased translational capacity (Fig. 1e, left) (Trinh et al. 2012) . Consistent with a recent report, hippocampal L-LTP was normally induced in PERK KO mice (Fig. 1a-c) (Trinh et al. 2014) . Notably, HFS-induced L-LTP in PERK KO mice sustained in the presence of rapamycin, indicating its independence of mTORC1 activity (Fig. 1a-c) .
We further used a pharmacological approach to suppress PERK activity by treating slices from wild-type (WT) mice with a selective PERK inhibitor GSK2606414 (1 lM) (Yang et al. 2016) . In contrast to the PERK KO findings, the PERK inhibitor failed to reverse L-LTP failure caused by rapamycin (Fig. 1d ) even though GSK2606414 effectively reduced eIF2a phosphorylation (Fig. 1e, right) . Taken together, repressing PERK activity through a chronic genetic but not acute pharmacological approach reverses L-LTP failure associated with mTORC1 inhibition.
L-LTP in PERK KO mice is blocked by the general mRNA translation inhibitor anisomycin We next asked whether the rapamycin-insensitive L-LTP in PERK KO mice was dependent on general protein synthesis by challenging the L-LTP with the general mRNA translation inhibitor anisomycin. In slices from WT mice treated with anisomycin (40 lM), L-LTP was blocked ( Fig. 2a and b) . Consistent with previous studies, the inhibitory effects of anisomycin were significant shortly after strong HFS (twotrain), and the E-LTP (independent of de novo protein synthesis) is rather transient, suggesting that a protein synthesis-dependent process contributed to LTP at a relatively early time point (Osten et al. 1996; Tsokas et al. 2005; Hernandez and Abel 2008) . Importantly, in slices from PERK KO mice treated with anisomycin, L-LTP was also significantly blocked, indicating its dependency on general protein synthesis (Fig. 2a and b) .
Genetic removal of eIF2a kinase GCN2 failed to rescue L-LTP failure induced by rapamycin To further investigate the mechanisms associated with the rapamycin-insensitive L-LTP in PERK KO mice, we performed electrophysiology experiments on a line of transgenic mice in which GCN2, another kinase of eIF2a, was genetically removed (Ma et al. 2013) . In slices from GCN2 KO mice, L-LTP was comparable to that of WT mice (Fig. 3a-c) . Surprisingly, treatment of slices with rapamycin (1 lM) blocked hippocampal L-LTP not only in WT mice but also in GCN2 KO mice (Fig. 3a-c) , contrasting the rapamycin-insensitive L-LTP in PERK KO mice (Fig. 1a-c) . In addition, we confirmed that, similar to PERK KO mice, eIF2a phosphorylation was also reduced in GCN2 KO mice (Fig. 3d) (Costa-Mattioli et al. 2005) . Therefore, deletion of GCN2 did not prevent rapamycin-induced L-LTP failure despite decreasing eIF2a phosphorylation, indicating a PERK KO-specific effect on rapamycin-resistant L-LTP.
Repression of either PERK or GCN2 activity does not affect the mTORC1 signaling cascade in hippocampus We further investigated whether the mTORC1 signaling cascade was affected in PERK or GCN2 knockout mice as a potential molecular mechanism for the L-LTP phenotypes described above. Western blot experiments were carried out on hippocampal slices and mTORC1 signaling was assessed using antibodies targeted to specific phosphorylation sites (Ma et al. 2010) . However, the experimental results did not reveal any effects of PERK or GCN2 deletion (as compared to WT mice) on mTORC1 signaling. Similar levels of mTOR phosphorylation at either the AKT-dependent site Ser2448 or its autophosphorylation site Ser2481 were detected in WT, PERK, and GCN2 mice (Tsokas et al. 2007) (Fig. 4a and b) . Neither PERK nor GCN2 KO hippocampi showed changes in p70S6K phosphorylation on either the mTORC1-dependent site Thr389 or mitogenactivated protein kinase/ERK-dependent sites Thr421/ Ser424 compared to WT (Tsokas et al. 2007) (Fig. 4c , and data not shown). Lastly, deletion of either PERK or GCN2 had no effect on 4E-BP1 phosphorylation on its mTORC1-dependent site Thr37/46 (Fig. 4e) . We also probed for levels of eEF1A, a translational elongation factor controlled by mTORC1-p70S6K signaling that is implicated in long-term hippocampal synaptic plasticity (Tsokas et al. 2005) . As shown in Fig. 4f , eEF1A levels were not altered in hippocampal slices from either GCN2 or PERK KO mice compared to relevant WT control mice. Additionally, treatment of slices with the PERK inhibitor GSK2606414 did not affect mTORC1 signaling, as indicated by unchanged phosphorylation levels of p70S6K and 4E-BP1 at mTORC1-dependent sites ( Fig. 4g and h ). Since activity of mTORC1 signaling was not affected by repression of the eIF2a kinases PERK or GCN2, it is unlikely to have contributed to the rapamycin-insensitive L-LTP phenotype associated with PERK KO mice.
A most recent study indicated that PERK can phosphorylate cyclic adenosine monophosphate response element binding protein (CREB) and PSD95 at the Ser129 and Thr19 residues, respectively (Sen et al. 2017) . To further investigate mechanisms underlying mTORC-1 independent L-LTP in PERK KO mice, we performed biochemical experiments to analyze the CREB and PSD95 phosphorylation in both GCN2 KO and PERK KO mice. However, hippocampal levels of phospho-CREB (Ser129) and phospho-PSD95 (Thr19) were not altered by reduction in either GCN2 or PERK (Fig. 4h and i) .
Genetic removal of PERK results in decreased eEF2 phosphorylation
In addition to mTORC1 and eIF2a control of translation initiation, de novo protein synthesis is regulated at the elongation phase through phosphorylation of eEF2 by its kinase eEF2K (Taha et al. 2013) . Multiple studies point to a crucial role of eEF2 phosphorylation in long-term synaptic plasticity and memory (Taha et al. 2013) . We therefore set out to examine the effects of PERK/GCN2 repression on eEF2 phosphorylation by performing western blot experiments on hippocampal tissue. We found that levels of phospho-eEF2 (Thr56) were not altered in GCN2 KO mice or hippocampal slices treated with the PERK inhibitor GSK2606414 (Fig. 5a and b) . However, genetic removal of PERK resulted in a significant reduction in eEF2 phosphorylation (Fig. 5c) , which is associated with an increased capacity for general protein synthesis (Kenney et al. 2014) . To gain insights into the cellular distribution of the regulation of eEF2 phosphorylation in PERK KO mice, we performed immunofluorescence combined with confocal microscopy on hippocampal slices. Consistent with the biochemical data, immunostaining for phosphorylated eEF2 was markedly lower in both the soma and dendrites of stratum radiatum hippocampal CA1 neurons in PERK KO mice compared with WT controls (Fig. 5d) . Furthermore, given that mTORC1 signaling was not altered by PERK deletion, we examined the activity of AMPK, another potential upstream regulator of eEF2K/eEF2 phosphorylation (Hardie 2014) . However, AMPK activity, as assessed by phosphorylation at the Thr172 site of its catalytic a subunit, was not affected by either pharmacological PERK inhibition or genetic removal of PERK ( Fig. 5f and g ). Interestingly, levels of phospho-AMPK were increased in hippocampi from GCN2 KO mice (Fig. 5e) . In summary, eEF2 phosphorylation was significantly decreased in PERK KO mice but not in GCN2 KO mice or with PERK inhibitor treatment. Furthermore, we investigated molecular signaling alterations in GCN2 KO and PERK KO mice with rapamycin treatment. We found that application of rapamycin (1 lM) on hippocampal slices from both mutant mice led to inhibition of mTORC1 activity, as demonstrated by decreased levels of p70S6K phosphorylation at the Thr389 site (Fig. 6a) . Additionally, levels of phospho-AMPK or phospho-eEF2 in either GCN2 KO or PERK KO mice were also reduced by rapamycin (Fig. 6b  and c) . Representative images of three independent experiments. (e and g) Western blot experiments showed that AMP-activated protein kinase (AMPK) phosphorylation was increased in hippocampal slices of GCN2 KO mice but unaltered in slices treated with GSK2606414 (1 lM) or hippocampal slices from PERK KO mice. Unpaired student's t-test, *p = 0.0318. n = 4-6 mice for each group with up to five technical replicates. Cumulative data were shown in bar graphs.
Rapamycin-induced L-LTP failure is prevented by genetic removal of eEF2 kinase Decreased eEF2 phosphorylation leads to increased translational capacity and thus may contribute to the protein synthesis-dependent, rapamycin-resistant LTP in PERK KO mice. With the findings described above, we hypothesized that reduction in eEF2 phosphorylation enables the expression of rapamycin-insensitive L-LTP in PERK KO mice. To directly test this hypothesis, we performed electrophysiology experiments on hippocampal slices from a line of transgenic mice with the gene encoding eEF2K, the only known kinase for eEF2 (Taha et al. 2013) , removed. While eEF2K removal dramatically inhibited eEF2 phosphorylation and increased de novo protein synthesis in hippocampal slices assessed by SUnSET experiment, it did not affect L-LTP as compared with WT controls (Fig. 7a-e) . Importantly, L-LTP sustained in slices from eEF2K KO mice in the presence of rapamycin (1 lM) (Fig. 7a-c) . These findings indicate that reduced phosphorylation of eEF2 and resulting increased protein synthesis can enable L-LTP independent of mTORC1 activity.
Discussion
Long-term forms of synaptic plasticity require novel protein synthesis. While identification of specific 'plasticity-related proteins' is under debate, a great deal of evidence has demonstrated that establishment of long-term memory and neuronal plasticity is associated with the regulation of multiple signaling pathways controlling general protein synthesis (Alberini 2008; Hoeffer and Klann 2010; Graber et al. 2013; Santini et al. 2014) . Given the central role of mTORC1 signaling in controlling cap-dependent mRNA translation initiation and synthesis of translational machinery, it is unsurprising that many forms of long-term memory and synaptic plasticity previously studied are blocked by rapamycin, the selective inhibitor of mTORC1 (Graber et al. 2013) . Meanwhile, several other molecular signaling cascades involved in general mRNA translation have also been linked to formation of memory and synaptic plasticity, including eIF2a and eEF2 phosphorylation (Taha et al. 2013; Trinh and Klann 2013) . How these molecules interact with mTORC1 in synaptic plasticity and memory remains unclear. One of the most interesting findings of this study is the mTORC1-independent L-LTP in mice with the genetic removal of PERK, a kinase for mRNA translational initiation factor eIF2. The mTORC1-independent L-LTP in PERK KO mice was blocked by the general protein synthesis inhibitor anisomycin, suggesting a compensating mechanism for mTORC1 inhibition involving other protein synthesiscontrolling signaling pathways. Perhaps, the most straightforward explanation would be that repression of PERK leads to eIF2a dephosphorylation and consequently increased protein synthesis . However, this is not likely the case based on our finding that rapamycin blocks hippocampal L-LTP in GCN2 KO mice in which eIF2a phosphorylation is also suppressed (Fig. 3d) (CostaMattioli et al. 2005) .
Our data strongly imply phosphorylation of translational elongation factor eEF2 as a molecular mechanism underlying mTORC1-independent L-LTP in PERK KO mice. As described, reduced phosphorylation of eEF2 leads to up-regulation of translation elongation and thus general protein synthesis (Taha et al. 2013) . We are the first to link PERK/eIF2a signaling to translational elongation regulation during long-term synaptic plasticity. Translation initiation is usually considered the rate-limiting step in de novo protein synthesis and is tightly controlled by signaling cascades, such as the mTORC1 and eIF2a pathways. Consistently, many studies have firmly demonstrated the importance of mTORC1 and eIF2a signaling in regulating long-term synaptic plasticity and memory formation (Tang et al. 2002; Costa-Mattioli et al. 2007; Ma et al. 2011; Zhu et al. 2011; Trinh et al. 2012) . Mounting evidence also points to a critical role of elongation regulation in mRNA translation, particularly during cellular responses to nutrient and energy deficiencies since most (>95%) of the energy and amino acids used in protein synthesis are consumed during the elongation phase (Browne and Proud 2002; Kenney et al. 2014). Furthermore, translational control at the elongation phase is important in neuronal dendrites where the capacity for protein synthesis is low. Thus, both initiation and elongation procedures need to be enhanced to achieve the extensive requirement of new protein synthesis for maintenance of long-term synaptic plasticity (Sutton and Schuman 2006) . How does genetic removal of PERK lead to suppression of eEF2 phosphorylation? Previous studies, mostly from non-neuronal systems, have identified multiple signaling molecules as upstream regulators in the eEF2K-eEF2 signaling network, including mTORC1 and AMPK (Horman et al. 2002; Hardie 2004 Hardie , 2014 . Briefly, activation of mTORC1 leads to inhibition of eEF2K, directly or indirectly through its downstream effector p70S6K, resulting in decreased eEF2 phosphorylation and consequently promotion of translation elongation. In contrast, AMPK stimulates activity of eEF2K, thus increasing eEF2 phosphorylation and repressing general protein synthesis (Hardie 2014; Kenney et al. 2014) . Interestingly, neither mTORC1 signaling nor AMPK activity was altered in PERK KO mice (Fig. 4 and 5) , indicating alternative mechanisms associated with the regulation of eEF2 phosphorylation. Usually, eEF2K is activated by increased intracellular Ca 2+ levels and Calmodulin (CaM) binding (eEF2K is also known as CaMKIII), leading to phosphorylation and inactivation of eEF2. Previous studies indicate that eEF2K activation in neuronal dendrites is dependent on glutamate signaling and N-methyl-D-aspartate receptor activation (Taha et al. 2013; Heise et al. 2014) . A recent study performed in cultured cortical mouse neurons showed that repression of PERK activity, either with the inhibitor GSK2606414 or genetic deletion, leads to impairments/reduction in G q proteincoupled intracellular Ca 2+ rise (Zhu et al. 2016) . While reduction in intracellular Ca 2+ in experiments with genetic PERK deletion may be responsible for the down-regulation of eEF2K activity and thus decreased eEF2 phosphorylation, we did not observe any effects of PERK inhibitor GSK2606414 on eEF2 phosphorylation or rapamycininduced L-LTP failure, likely because of different consequences of the acute (pharmacological inhibition) versus chronic (genetic knockout) suppression of PERK activity. Future studies are warranted to elucidate the detailed mechanisms associated with repression of eEF2 phosphorylation and genetic removal of PERK in neurons.
